Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score

Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis

(2020) Natalie A. Schwehr et al.   DRUGS & AGING

Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity

(2020) Anne-Laure Kaminsky et al.   JOURNAL OF NEUROLOGY

SUSTAINED DISEASE REMISSION AFTER DISCONTINUATION OF DISEASE MODIFYING TREATMENTS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS

(2020) Matteo Pasca et al.   Multiple Sclerosis and Related Disorders

Epidemiology and treatment of multiple sclerosis in elderly populations

(2019) Caila B. Vaughn et al.   Nature Reviews Neurology

Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60

(2019) Le H. Hua et al.   Multiple Sclerosis and Related Disorders

Current therapeutic landscape in multiple sclerosis

(2019) Bruce A.C. Cree et al.   CURRENT OPINION IN NEUROLOGY

Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies

(2019) Marisa P McGinley et al.   Multiple Sclerosis Journal

Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes

(2019) Hajime Yano et al.   Multiple Sclerosis and Related Disorders

Disease-modifying treatments for early and advanced multiple sclerosis

(2018) Gavin Giovannoni   CURRENT OPINION IN NEUROLOGY

‘No evidence of disease activity’ - is it an appropriate surrogate in multiple sclerosis?

(2018) H. Hegen et al.   EUROPEAN JOURNAL OF NEUROLOGY

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

(2018) Alan J Thompson et al.   LANCET NEUROLOGY

Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60

(2018) Le H Hua et al.   Multiple Sclerosis Journal

Factors Predictive of Severe Multiple Sclerosis Disease Reactivation After Fingolimod Cessation

(2018) Ugur Uygunoglu et al.   NEUROLOGIST

Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60

(2018) Le H Hua et al.   Multiple Sclerosis Journal

Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS – YES

(2017) Ilya Kister   Multiple Sclerosis Journal

Is there a safe time to discontinue therapy in MS?

(2017) Mark S. Freedman   Nature Reviews Neurology

Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS – YES

(2017) Ilya Kister   Multiple Sclerosis Journal

Defining secondary progressive multiple sclerosis

(2016) Johannes Lorscheider et al.   BRAIN

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

(2016) Ilya Kister et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors

(2016) Gabriel Bsteh et al.   Multiple Sclerosis Journal

Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors

(2016) Gabriel Bsteh et al.   Multiple Sclerosis Journal

Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study

(2016) Gabriel Bsteh et al.   PLoS One

Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients

(2014) Per Soelberg Sorensen et al.   JOURNAL OF NEUROLOGY

Significant clinical worsening after natalizumab withdrawal: Predictive factors

(2014) A Vidal-Jordana et al.   Multiple Sclerosis Journal

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity

(2011) Małgorzata Siger et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Measures in the first year of therapy predict the response to interferon β in MS

(2009) J Río et al.   Multiple Sclerosis Journal